Oncolytics Biotech Inc. (NASDAQ:ONCY – Free Report) – Analysts at HC Wainwright upped their FY2024 EPS estimates for Oncolytics Biotech in a research report issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.28) per share for the year, up from their previous forecast of ($0.30). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q1 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.28) EPS, FY2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.09) EPS and FY2028 earnings at $0.41 EPS.
Several other equities research analysts also recently commented on the stock. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, November 13th. Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.
Oncolytics Biotech Stock Up 3.2 %
NASDAQ ONCY opened at $0.72 on Wednesday. Oncolytics Biotech has a 52 week low of $0.67 and a 52 week high of $1.53. The firm’s 50-day simple moving average is $0.85 and its two-hundred day simple moving average is $0.97.
Institutional Investors Weigh In On Oncolytics Biotech
An institutional investor recently bought a new position in Oncolytics Biotech stock. Vantage Point Financial LLC purchased a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 29,744 shares of the company’s stock, valued at approximately $27,000. Hedge funds and other institutional investors own 6.82% of the company’s stock.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
- Five stocks we like better than Oncolytics Biotech
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Investing in Commodities: What Are They? How to Invest in Them
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
